Am J Physiol Endocrinol Metab 2012;303:E253-64.ArticlePubMed 72
Foundayo godkndes som lkemedel av amerikanska FDA i april i r
FOR LIRAGLUTIDE SOURCE: MedlinePlus
Most insurance plans don't cover GLP-1 medications specifically for weight loss, leaving patients responsible for the full cost unless they meet specific medical criteria
Am ERA-Kongress 05/2024 wurde gleichzeitig eine neue Metaanalyse mit 8 GLP-1 RA-Studien (inkl
Certain factors may increase the likelihood of experiencing bloating on GLP-1 therapy, including: Pre-existing gastrointestinal conditions such as irritable bowel syndrome (IBS), functional dyspepsia, or small intestinal bacterial overgrowth (SIBO) Rapid dose escalation without adequate titration periods Dietary factors , particularly high intake of fermentable carbohydrates (FODMAPs), fatty foods, or carbonated beverages Concurrent medications that affect gastrointestinal motility Patients should be aware that GLP-1 receptor agonists have been associated with more serious gastrointestinal adverse effects, including pancreatitis (inflammation of the pancreas) and gallbladder disease
